Table 2.
Treatment exposure in the Asian subpopulation of CheckMate 9LA
| NIVO + IPI + chemoa (n = 28) | Chemob (n = 30) | |
|---|---|---|
| Duration of therapy, median (range), months | 4.2 (0.0–17.6) | 2.1 (0.0–15.9) |
| Number of doses received, median (range) | ||
| Nivolumab | 7 (1–25) | NA |
| Ipilimumab | 4 (1–13) | |
| Cycles of platinum-based chemotherapy received, n (%) | ||
| 1 | 2 (7) | 1 (3) |
| 2 | 26 (93) | 5 (17) |
| 3 | 0 | 5 (17) |
| ≥ 4c | 0 | 19 (63) |
| Patients receiving pemetrexed maintenance therapy,d n (%) | NA | 12e (40) |
| Patients still on treatment, n (%) | 5 (18) | 1 (3) |
aNivolumab plus ipilimumab combined with chemotherapy (2 cycles)
bChemotherapy alone (4 cycles, with optional pemetrexed maintenance for nonsquamous histology)
cIncludes patients who completed 4 cycles of platinum-doublet chemotherapy and patients with nonsquamous histology who received pemetrexed maintenance
dPemetrexed maintenance therapy was optional for patients with nonsquamous histology
e57% of patients with nonsquamous histology
Chemo chemotherapy, IPI ipilimumab, n number of patients, NA not available, NIVO nivolumab